SCHEMBL5651276

SCHEMBL5651276

CCOC(=O)c1sc2c(ccc(=O)n2CC2CCNCC2)c1-c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAT P00750 1/20 0.40
MAPK8 P45983 1/20 0.38
HPGD P15428 4/20 0.37
KDM4E B2RXH2 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 6/20 0.37
MAPT P10636 2/20 0.37
HSD17B10 Q99714 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CDC7 O00311 1/20 0.37
TRPM8 Q7Z2W7 1/20 0.37
DBF4 Q9UBU7 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
GRM6 O15303 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CSF1R P07333 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651283 0.93 MAPK8 (0.40) MAPK8HPGDKDM4ENPC1RAB9A
SCHEMBL5647564 0.91 MAPK8 (0.47) MAPK8HPGDKDM4ENPC1RAB9A
SCHEMBL27617046 0.87 MAPK8 (0.40) MAPK8
SCHEMBL5650258 0.86 LMNA (0.38) MAPK8HPGDKDM4ESMN1; SMN2ALDH1A1
SCHEMBL5651246 0.84 SMN1; SMN2 (0.42) HPGDKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL5651454 0.80 ALDH1A1 (0.54) MAPK8SMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL5650265 0.79 PLAT (0.37) PLATHPGDKDM4ENPC1RAB9A
SCHEMBL2781580 0.79 CNR2 (0.43) HPGDKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL5652931 0.79 ACACB (0.53) MAPK8HPGDKDM4ENPC1RAB9A
SCHEMBL5648783 0.79 LMNA (0.45) HPGDKDM4ENPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 PLAT 4042/4885MAPK8 22/4885HPGD 1929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.